The protective effect of Er-Xian decoction against myocardial injury in menopausal rat model

Zhiguo Zhang¹, Lihua Xiang¹, Lanping Zhao², Hong Jiao², Zhen Wang¹, Yubo Li¹ and Yanjing Chen¹*

Abstract

Background: Er-Xian decoction (EXD), a formula of Chinese medicine, is often used to treat menopausal syndrome in China. The aim of the present study was to explore the potential cardioprotective mechanism of EXD against myocardial injury in an ovariectomy-induced menopausal rat model.

Methods: We divided the female Wistar rats into ovariectomy group and sham operation group (SHAM group). The ovariectomized (OVX) rats received treatment of vehicle (OVX group), EXD (EXD group) or 17β-estradiol (E2 group). After 12-week of treatment, the level of estradiol in serum was detected using an electrochemiluminescence immunoassay, and electrophysiologic changes in myocardial action potentials (AP) were evaluated using intracellular microelectrode technique. Changes in the histopathology of the left ventricle and the ultrastructure of the cardiomyocytes were observed by hematoxylin and eosin (HE) staining and transmission electronmicroscopy to assess myocardial injury. Microarrays were applied for the evaluation of gene expression profiles in ventricular muscle of the OVX and EXD rats. Further pathway analyses of the differential expression genes were carried out using the Kyoto Encyclopedia of Genes and Genomes (KEGG). And real-time quantitative RT-PCR (qRT-PCR) was used for verification of the key findings.

Results: The results from electrophysiological and histomorphological observations demonstrated that EXD had a substantial myocardial protective effect. The EXD-treated rats, in comparison with the OVX rats, demonstrated up-regulated expression of 28 genes yet down-regulated expression of 157 genes in the ventricular muscle. The qRT-PCR assay validated all selected differential expression genes. The KEGG pathway analysis showed that the down-regulated genes were relevant to cardiomyopathy and myocardial contractility. EXD could decrease the mRNA expressions of cardiac myosin (Myh7, Myl2) and integrin (Itgb5) in the ventricular myocardium.

Conclusion: EXD had a protective effect against myocardial injury in OVX rats, and this cardioprotective effect may be associated with modulation of the expression of cardiac myosin or integrin at the mRNA level.

Keywords: Er-Xian decoction, Cardioprotective effect, Cardiomyopathy, Menopause, Ovariectomy

Background

During the menopausal period, many physiologic and pathologic changes occur in this crucial stage for women because hormonal changes significantly influence several systems and organs. The cardiovascular system also suffers from structural or functional impairment [1–3]. Several studies showed that estrogen deficiency increased cardiovascular risk factors and subsequently increased cardiovascular morbidity and mortality [4, 5], and myocardial injury can take place in asymptomatic women in postmenopause [6, 7]. It is believed that the higher risk associated with early menopause is due to longstanding deprivation of endogenous estrogen, which may influence cardiovascular risk through a variety of effects on metabolism and vascular function [8]. Though hormone therapy had a protective effect on the myocardium of menopausal women [9, 10], some randomized controlled trials have shown conflicting study results [11, 12]. In addition, HT could lead to
increased incidence of breast cancer and thromboembolic disease in women [13, 14]. Therefore, an effective and safe substitutional treatment should be brought forward to decrease the risk of myocardial injury in menopausal women.

The ovariectomized (OVX) rat is a suitable animal model to mimic the estrogen withdrawal of postmenopausal women [15, 16]. Some studies had shown OVX rat could undergo myocardial injury induced by ovariectomy [17–19], and estrogen had a protective effect against this myocardial injury [20, 21]. Er-Xian Decoction (EXD), a Chinese herbal formula, has been proven to reduce the severity and frequency of hot flushes and ameliorate menopausal symptoms in perimenopausal women without serious adverse events [22]. Moreover, a study based on menopausal rat model revealed that EXD showed an estrogen-like effect in the relief of menopausal syndrome [23, 24]. Naturally, we hypothesized that EXD could have a cardioprotective effect on menopausal animal models. In this study, we explored the protective role of EXD on cardiac structure and function in a menopausal rat model induced by ovariectomy.

Methods
Herbal materials
Herba Epimedii, Radix morinae Officinalis, Radix Angelicae Sinensis, Rhizoma Anemarrhenae, Cortex Phellodendri and Rhizoma Curculiginis were purchased from Beijing Tongrentang (Bozhou) Prepared Slices of Chinese Crude Drugs Co., Ltd (Beijing, China), and by a pharmacist of traditional Chinese medicine (Feng Sui) in Institute for Chinese Materia Medica, China Academy of Chinese Medical Sciences. All voucher specimens are deposited in the herbarium center of China Academy of Chinese Medical Sciences.

Preparation of EXD
We extracted a mixture of six herbal medicines (250 g of each herbal medicine, one thousand five hundred grams in total) by decoction with 10× (v/w) distilled water at the temperature of 100 °C for 2 h. After filtration, we boiled the residue for another 1 h, and mixed the filtrates together, then preserved at 4 °C after lyophilized using a freeze drier (Labconco, Freezone). The yield of the dried extract from the initial crude materials was 10%. We dissolved the extracts to 30 and 60 mg/ml by adding water, and then administered to the rats orally with a dose of 0.1 ml/kg body weight.

Animal studies
In this study, seventy-two virgin Sprague-Dawley rats aged six months and weighing approximately 310 ± 20.0 g were acquired from the Experimental Animal Center in National Institutes for Food and Drug Control of China (SCXK (JING) 2009–0017, Beijing, China). The protocol involving animals in this study was authorized by The Institutional Ethics Committee of China Academy of Chinese Medical Sciences (Approval number: 2015–010). The sham operation (n = 18, SHAM group) or bilateral OVX (n = 54) using a dorsal incision [25] was performed on the rats after acclimatization. The rats undergoing OVX were divided into three groups based on the treatment agents, including vehicle (OVX group), EXD (EXD group) and 17β-estradiol (E2 group). Each group included eighteen rats. Subsequently, we dissolved 17β-estradiol (Sigma-Aldrich, USA) in absolute ethanol and diluted with olive oil. The preparation was used for daily subcutaneous injection of the E2 group rats at a dose of 30 μg/kg body weight. EXD was dissolved in aqua destillata and orally force-fed to the EXD group rats at a dosage of 7.5 g raw herbs/kg body weight/day, which was calculated using the human recommended dosage proposed by the Chinese Pharmacopeia and the surface area ratio of rats and humans. The OVX and SHAM rats were orally force-fed equal quantities of aqua destillata and standardized rat food was given to all rats throughout the current study. The rats were treated with agents or aqua destillata seven days after operation and the treatment lasted until the 13th week. The body weight of each subject was measured once a week.

Arrangement of the specimens
On the day after final treatment, xylazine (12 mg/kg) and ketamine (80 mg/kg) were injected intraperitoneally to anesthetize all animals, which were subsequently exsanguinated for sacrifice.

Half of the rats in each group (n = 9) were used for an isolated heart perfusion assay. For the isolated heart perfusion assay, we removed the rat hearts rapidly and excised the left ventricular papillary muscles. The arrangement process was conducted in a plexiglas chamber which allowed continuous superfusion.

The other rats in each group (n = 9) were used for the rest experiments. In the rest experiments, the uteri of the rats were excised and immediately weighed and the aorta abdominals was punctured before the rats died to collect blood specimens into tubes. Then, serum was prepared by centrifugation (2000 rpm for 20 min) and preserved at −80 °C before use to determine the level of estradiol. The left ventricle of the heart was removed. We fixed a piece of the left ventricle in 4% paraformaldehyde, after fixation we dehydrated in graded ethanol and then embedded in paraffin. Then, the paraffin-embedded tissues were cut into sections (5-μm thickness) and subjected to hematoxylin and eosin (HE) staining. Another piece of the left ventricular tissue was used for observation under a transmission electron microscope (TEM). The remaining left ventricular tissue was preserved at −80 °C to conduct the real-time quantitative RT-PCR (qRT-PCR) and microarrays assays.
Measurements of estradiol in serum
The estradiol concentration in the serum was detected using an electrochemiluminescence immunoassay (ECLIA) Assay Kit purchased from Roche Diagnostics (Mannheim, Germany) in accordance with the instructions. All measurements were performed according to the manufacturers' protocols.

Electrophysiologic studies
We removed the rat hearts rapidly and placed in Krebs-Henseleit buffer (oxygenated, 4 °C) for removal of the extracardiac tissue. The sample (4 mm × 4 mm) was cut from the left ventricle and then pinned on a thin silicon disc at the bottom of a perfusion chamber. Thereafter, the sample was perfused (4 mL/min) with Krebs-Henseleit solution which contained (in mM) 121 NaCl, 5 KCl, 1.2 MgSO₄, 2 CaCl₂, 25 NaHCO₃, 1.2 NaHPO₄, and 11 glucose. Finally, the sample was equilibrated with 5% CO₂ in O₂ at 36 ± 0.5 °C and the pH was 7.36–7.42.

The whole process was stimulated at a frequency 1 Hz by 1 ms square pulse 1.5 times threshold voltage. We recorded and analyzed transmembrane action potentials (APs) using intracellular microelectrode technique (Chengyi, China). The variables measured were resting membrane potential (RMP), AP amplitude (APA), the maximal rate of depolarization (Vmax), and AP duration at 50% and 90% (APD₅₀ and APD₉₀).

Histological studies
The fixture of the heart was carried out by dipping into 10% neutral buffered formalin. Parallel to the atrioventricular groove were serial sections for 5 μm made. Standard HE staining was used for the histomorphological evaluation.

Ultrastructure observation
At the end of reperfusion, we cut fresh myocardium tissue (1 mm³) off from about the middle of the apex and the ligation point, then prefixed with 2.5% glutaraldehyde and stored at 4 °C until processed. The post-fixture was accomplished using 1% osmium tetroxide. Then, after dehydration with gradient ethanol, we dipped the specimens in propylene oxide, and embedded with epoxy resin. Afterwards, we made them into ultrathin sections (0.1 μm). Finally, we stained the sections with lead-uranium and observed the changes in the ultrastructural organization by a TEM (HITACHI-S3400 N, Japan).

Microarray data analysis
We conducted the gene microarray assay using KangChen Bio-tech (Shanghai, China). The microarrays used in the present study were whole-genome gene expression profiling chips (4 × 44 K) containing about 41,000 probes for rat genes, which were purchased from Agilent Technologies. The collection of total RNA of the left ventricular tissue from the EXD group and the OVX group as well as a DNase digestion step was accomplished with the help of the RNase kit (Qiagen) and TRIzol (Invitrogen) according to the instructions. We amplified and labeled the samples with the help of an Agilent Quick Amp labeling kit, then we hybridized the samples using an Agilent whole-genome oligo microarray, following RNA measurement by the NanoDrop ND-1000 and denaturing gel electrophoresis. All the processes were conducted in Agilent’s Sure-Hyb Hybridization Chambers. We scanned the processed slides with the help of the Agilent DNA microarray scanner following hybridization and washing, in accordance with the settings provided by Agilent Technologies. We extracted the text files generated out of the Agilent Feature Extraction Software. Then input them into the version 11.0 of Agilent GeneSpring Software in order to analyze deeply. The gene expression level of the OVX group was considered as normal. Fold changes (≥2.0) and t-test p value (≤0.05) screening were applied for the identification of differentially expressed genes.

Pathway analysis
We used the Kyoto Encyclopedia of Genes and Genomes (KEGG) [26] for the pathway analysis to explore the potential role specific genes played in certain biological processes. We imported the differential expression genes between the EXD group and OVX group into the KEGG and the top pathways (P values<0.01) associated with myocardial morphology or functions were observed.

qRT-PCR analysis
We purified total RNA with the help of an RNase Mini Kit (Qiagen), then reverse-transcribed 4 μg of RNA to cDNA with the help of the Superscript First Strand synthesis system (Invitrogen). Afterwards, with the help of an ABI-7500 Sequence Detection System (Applied Biosystems), we performed qRT-PCR amplification with SYBR-green according to the instructions, which could detect PCR products in real time. Initiation of the PCR program was at 95 °C for 10s before 40 thermal cycles, then at 95 °C for 5 s and at 60 °C for 34 s. The data were analyzed in accordance with the 2−ΔΔCt method and in each sample, the results were normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase (Gapdh). To guarantee the purity of the amplification products, we created melting curves for each of the PCR reactions. Each of the experiments was matched with a no-template negative control.

Statistical analysis
All the values were presented in the way of mean ± standard deviation. SPSS 13.0 (SPSS Inc.) was applied
for all statistical analyses. The least significant difference (LSD) test and the analysis of variance (ANOVA) were applied for the test of differences between groups concerning the evaluated parameters. The data of all groups went through normality test by the method of Kolmogorov-Smirnov test. Statistical significance was defined as $P$ value $< 0.05$.

**Results**

**Effect of EXD on the weights of bodies and uteri**

Figure 1 shows that the SHAM rats weighted remarkably less compared with the OVX rats. Both E2 and EXD could remarkably inhibit weight gain induced by OVX during the twelve-week treatment.

Compared with the SHAM group, OVX caused remarkable atrophy of the uterus, indicating a successful operation. The administration of E2 or EXD remarkably relieved the atrophy of uterine tissue compared with the OVX rats (Fig. 2).

**Effect of EXD on the level of estradiol in serum**

Figure 3 shows the serum concentrations of estradiol in different rats after treatment for twelve weeks. After the 12-week treatment, the levels of estradiol in the SHAM rats were remarkably higher in comparison with the OVX rats ($p < 0.01$). In addition, the levels of estradiol in the EXD and E2 rats were remarkably lower in comparison with the OVX group rats.

**Effect of EXD on ventricular action potentials**

Table 1 shows the effects of EXD on the ventricular action potential variables of model rats after treatment for twelve weeks. Compared with the SHAM group, OVX caused remarkable reductions in APD$_{50}$ and APD$_{90}$, and E2 or EXD could inhibit the reduction in APD$_{50}$ significantly.

**Effect of EXD on cardiomyocyte ultrastructural changes**

The ultrastructures of cardiomyocytes from the SHAM rats demonstrated as normal (Fig. 5a), while the ultrastructures of cardiomyocytes from the OVX group rats demonstrated marked damages, which appeared as
swollen and damaged mitochondria, intracellular edema, and myofibrillar derangements and ruptures (Fig. 5b). In contrast, significant decreases were observed in multiple characteristics of cardiomyocyte ultrastructural damages in the E2-or EXD-treated rats (Fig. 5c-d). All these features were ameliorated following EXD administration.

**Effect of EXD on gene expression profiles**

The array data turned out that the expressions of 185 genes were changed (≥2-fold, \( P \leq 0.05 \)) between the ventricular muscles of the EXD and OVX rats. More precisely, 28 genes were up-regulated and 157 genes down-regulated (see Additional file 1).

**Pathway analysis of the differential expression genes**

Based on the differential expression genes, we retrieved the top pathways (\( P \leq 0.01 \)) associated with myocardial morphology or function (Table 2) using the KEGG database. No pathway associated with down-regulated differentially expressed genes was found.

**Confirmation of the differential expression genes by qRT-PCR**

To validate the differential expression genes, we chose 7 genes, including myosin light chain 3 (Myl3), myosin heavy chain 7 (Myh7), integrin subunit beta 5 (Itgb5), titin (Ttn), actinin alpha 2 (Actn2), catenin alpha 3 (Ctnna3), and lymphoid enhancer binding factor 1 (Lef1), which were involved in significant pathways in Table 2 and were associated with myocardial morphology or function. The primers of genes were listed in Table 3. The changes of these genes determined by qRT-PCR are shown in Fig. 6. In general, the results from qRT-PCR of all cases were consistent with the results identified in microarray analysis.

### Table 1 Effect of EXD on ventricular action potentials

| Group | RMP (mV) ± SD | Vmax (V/s) ± SD | APA (mV) ± SD | APD\(_{50}\) (ms) ± SD | APD\(_{90}\) (ms) ± SD |
|-------|--------------|----------------|--------------|-----------------|-----------------|
| SHAM  | −65.04 ± 6.01| 10.05 ± 3.72   | 85.45 ± 17.04| 50.32 ± 1.85    | 114.78 ± 16.03  |
| OVX   | −68.05 ± 4.51| 10.98 ± 4.78   | 90.35 ± 10.12| 34.75 ± 4.42**  | 89.14 ± 7.09*   |
| E2    | −60.88 ± 8.07| 7.32 ± 2.24    | 82.59 ± 10.27| 43.55 ± 3.07#   | 90.58 ± 11.87   |
| EXD   | −66.14 ± 9.20| 8.08 ± 3.22    | 88.97 ± 13.54| 44.00 ± 4.01#   | 95.59 ± 17.18   |

SHAM: sham-operated, OVX: ovariectomized, E2: 17β-estradiol, EXD: Er-Xian decoction, RMP: resting membrane potential, Vmax: maximal rate of depolarization, APA: AP amplitude, APD\(_{50}\): AP duration at 50%, APD\(_{90}\): AP duration at 90%. Values are presented as the means ± SD (\( n = 9 \) in each group). * \( P < 0.05 \) versus SHAM group; ** \( P < 0.01 \) versus SHAM group; # \( P < 0.05 \) versus OVX group.
Discussion

In the current study, following ovariectomy, treatment with EXD or E2 for 12 weeks prevented the loss of uterine wet weight and body weight gain in OVX rats resulting from a lack of estrogen (Figs. 1 and 2). In addition, the results from the ECLIA assay showed that the serum estradiol levels of the EXD or E2 group rats were remarkably higher in comparison with the OVX group rats. We inferred that EXD has a slight estrogen-like effect that could slow down uterine atrophy and weight gain resulting from OVX.

Relationships were observed between contractility, action potentials and repolarization. During the plateau phase (phase 2) of the AP, characterized by a balance between inward calcium and outward potassium ions, a high concentration of intracellular calcium contributes to a cascade of actions that generate the mechanical contraction of myocardial cells [27].

Table 2 Top pathways associated with down-regulated differentially expressed genes between the EXD group and OVX group

| Pathways                                      | p Value   | FDR      | Genes                  |
|-----------------------------------------------|-----------|----------|------------------------|
| Hypertrophic cardiomyopathy                   | 5.47 x 10^-5 | 0.005753 | Itgb5, Myh6, Myh7, Myl2, Myl3, Tnn |
| Dilated cardiomyopathy                        | 6.23 x 10^-5 | 0.005753 | Itgb5, Myh6, Myh7, Myl2, Myl3, Tnn |
| Cardiac muscle contraction                    | 5.01 x 10^-4 | 0.034695 | Myh6, Myh7, Myl2, Myl3, Myl4 |
| Tight junction                                | 7.56 x 10^-4 | 0.041881 | Actn2, Ctnna3, Myh13, Myh6, Myh7, Myl2 |
| Arrhythmogenic right ventricular cardiomyopathy | 2.70 x 10^-3 | 0.124520 | Actn2, Ctnna3, Itgb5, Lef1 |
| Adrenergic signaling in cardiomyocytes        | 6.10 x 10^-3 | 0.212027 | Myh6, Myh7, Myl2, Myl3, Myl4 |
| Viral myocarditis                             | 6.12 x 10^-3 | 0.212027 | Myh6, Myh7, RT1-CE7, RT1-T18 |
expression genes in the ventricular myocardium of the EXD group in comparison with the OVX group by microarray and identified key pathways with the KEGG. Based on the down-regulated differentially expressed genes, seven KEGG pathways associated with cardiomyopathy were retrieved (P values<0.01, Table 2).

Sarcomeric proteins constitute approximately 80% of myofibril mass. The levels of multiple isoforms and post-translational modifications determine sarcomeric function. The sarcomeric proteins included several types, such as regulatory proteins (like troponins and tropomyosin), contractile proteins/myofilament proteins (like myosin and actin), and cytoskeletal proteins (like myosin binding protein C and titin). The force and motion generated by the myocardium come from myosin coupling its ATPase activity to its cyclic interaction with actin. Myosin consists of myosin heavy (Myh) chains and essential and regulatory myosin light (Myl) chains [37]. The cardiac myosin heavy chains of mammals possess two isoforms, the α-isofrom and the β-isofrom, which are encoded by two different genes, Myh6 and Myh7 [38]. More than ten myosin light chain isoforms have been discovered in skeletal muscle, smooth muscle and cardiac atrial muscle. Myl2 is a regulatory myosin light chain and Myl3 and Myl4 are essential myosin light chains [39].

In both menopausal women and in animal models, a lack of female hormones causes substantial myocardial injury [31, 40]. Many studies have indicated that female sex hormone deprivation induced by OVX shifted the expression of cardiac Myh chain isoforms from predominantly α-isofroms toward more β-isofroms [41, 42]. However, the expression of regulatory Myl chains in the myocardium of OVX mice or humans increased [43, 44]. Estrogen supplementation consistently abolished all these changes [45, 46]. In the present study, we found that EXD could decrease the expressions of Myh7 and Myl2 at the mRNA level in the ventricular myocardium, which could be one of the mechanisms of EXD inhibition of myocardial injury.

Integrins are a set of cell surface receptors involved in cellular adhesion and signaling. What's more, they are considered as mechanotransducers in the circumstance of continuously contracting myocardium [47–49]. They have been associated with the progress of cardiac fibrosis or remodeling [50]. Cardiac fibroblasts can express αvβ5 integrin, which plays an importance part in cardiac remodeling via extracellular matrix-integrin interactions [51]. Our results from microarray and qRT-PCR demonstrated that the expression of Itgb5 in EXD group rats significantly decreased in comparison with OVX group rats. We inferred that EXD may mitigate myocardial fibrosis in OVX rats by decreasing the expression of Itgb5.

### Table 3 Primers used for qRT-PCR analysis

| Transcript | Sequence (5’-3’) |
|------------|-----------------|
| Gapdh      | F:5’GCTCTCTGCTCTCCCTGTCTA3’ | R:5’TGGTAAACGGCCCTCGGTAT3’ |
| Myh7       | F:5’TGCCTGTATTTGCTGCATTG3’ | R:5’AGGAGTTATTCATCCGAACTGTC3’ |
| Myβ        | F:5’SAAAGAACAAAGAGACCGGCCGAC’ | R:5’GTCGACATTATGGTTGGAGAAG3’ |
| Itgb5      | F:5’GAAAGCCCATTCACACATACT3’ | R:5’CATCGAGCCATTGTAGGATTGT3’ |
| Ctnna3     | F:5’AAGTCCGAAAAAGAGCAAGACG3’ | R:5’GAAGAGGCACATGACATCAGT3’ |
| Tm         | F:5’CCTGCGGTGGAAGGAGAAATC3’ | R:5’GTTGTCAGCTCGTCCGTTG3’ |
| Actn2      | F:5’TTGCCCACTGGGATGATATT3’ | R:5’TAGCAAACCTCTCTGCCTCTCC3’ |
| Lef1       | F:5’CAAGGTCACTGCTGTTATCC3’ | R:5’GGAAGCTGCTCCCTGAAAGTAGA3’ |
Many studies proved that EXD could show estrogen-like effect [23, 32], and no toxicity about EXD was reported so far. In this research, we only explored the cardioprotective effect of EXD in an animal model. A line of studies had to be performed before EXD became a promising alternative preventive and therapeutic agent for myocardial injury in postmenopausal females.

**Conclusions**
Based on the results from the electrophysiological test, histomorphological observations, microarray assay, pathway analysis and qRT-PCR validation, the current study demonstrated that treatment with EXD could lead to a cardioprotective effect against myocardial injury in OVX rats by modulating the expression of cardiac myosin or integrin at the mRNA level. Our study provided experimental evidence for EXD used as a drug for myocardial injury in postmenopausal females.

**Additional file**

Additional file 1: Differentially expressed mRNA. This file listed 185 differentially expressed mRNA (≥2-fold, \(P \leq 0.05\)) between the ventricular muscles of the EXD and OVX rats. (XLSX 17 kb)

**Abbreviations**
- AP: Action potential; APA: AP amplitude; APD50 and APD90: AP duration at 50% and 90%; ECLIA: Electrochemiluminescence immunoassay; EXD: Er-Xian decoction; HE: Hematoxylin and eosin; Ito: Outward potassium current; KEGG: Kyoto encyclopedia of genes and genomes; OVX: Ovariectomized; RMP: Resting membrane potential; TEM: Transmission electron microscope; Vmax: Maximal rate of depolarization

**Funding**
The work on herbal medicine was supported by grant from the National Natural Science Foundation of China (81473450) and the work on animal experiment was supported by the Fundamental Research Funds for the Central Public Welfare Research Institutes (YF-1318).
Availability of data and materials
All data generated or analyzed during this study are included in this published article. The raw used and/or analyzed during the current study can be available from the corresponding author on reasonable request.

Authors’ contributions
YC and ZZ conceived this study and wrote the manuscript. ZZ, LX, LZ, HI, ZW and YL carried out the experiments and contributed to the acquisition or interpretation of data. LX, LZ, HI and ZW contributed to preparation of EXD; ZZ and YL executed statistical analysis. ZZ, YC, LX, LZ and HI contributed to manuscript preparation. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All experimental procedures were approved by the Institute of Basic Theory, Ethics approval and consent to participate

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Institute of Basic Theory, China Academy of Chinese Medical Sciences, Beijing 100700, China. 2Basic Medical College, Hebei North University, Zhangjiakou 075000, Hebei, China.

Received: 22 March 2018 Accepted: 22 August 2018

Published online: 03 September 2018

References
1. Dogan U, Dogan NU, Baysar AO, Yıldırım S, Celik C, Incesu F, Ozdemir K, P-wave parameters and cardiac repolarization indices: does menopausal status matter? J Cardiol. 2012;60:333–7.
2. Schilacci G, Verdeccia P, Borgiaioni C, Giucci A, Porcellati C. Early cardiac changes after menopause. Hypertension. 1998;32:764–9.
3. Hinderliter AL, Sherwood A, Blumenthal JA, Light KC, Girdler SS, McFetridge J, Johnson K, Waugh R. Changes in hemodynamics and left ventricular structure after menopause. Am J Cardiol. 2002;89:330–3.
4. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989;321:641–6.
5. Bonithon-Kopp C, Scarabin PY, Dame B, Malmjac A, Guize L. Menopause-related changes in lipidoproteins and some other cardiovascular risk factors. Int J Epidemiol. 1990;19:942–8.
6. Chien CL, Wu YW, Yang WS, Yang PC, Su HM, Wu YT. Myocardial perfusion image in asymptomatic postmenopausal women with physical inactivity and overweight. Obesity facts. 2011;1:372–8.
7. Parashar S, Reid KJ, Spertus JA, Shaw LJ, Vaccarino V. Early menopause predicts angina after myocardial infarction. J Am Coll Cardiol. 2012;60:333–7.
8. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–11.
9. Godstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933–41.
10. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. The writing group for the PEPI trial. JAMA. 1995;273:199–208.
11. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) research group. JAMA. 1998;280:605–13.
12. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.
13. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Paity BM, Stafford RS, Sidney S, Rosendaal FR. Women’s Health Initiative. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292:1573–80.
14. Hsia J, Criqui MH, Rodabough RJ, Lander RG, Resnick HE, Phillips LS, Allison M, Bonds DE, Masaki K, Caralis P, et al. Estrogen plus progestin and the risk of peripheral arterial disease: the Women’s Health Initiative Circulation. 2004;109:520–6.
15. Federici LM, Roth SD, Krier C, Fitz SD, Skar T, Shekhar A, Carpenter JS, Johnson PL. Angiogenic CO2 stimulus elicits exacerbated hot flash-like responses in a rat menopause model and hot flashes in postmenopausal women. Menopause. 2016;23:1257–66.
16. Minami A, Matsushita H, Ieno D, Matsuda Y, Horii Y, Ishi A, Takahashi T, Kanazawa H, Wakatuki A, Suzuki T. Improvement of neurological disorders in postmenopausal model rats by administration of royal jelly. Clinicarctic. 2016;19:568–73.
17. Tang Z, Wang Y, Zhu X, Ni X, Lu J. Exercise increases cystathionine-gamma-lyase expression and decreases the status of oxidative stress in myocardium of Ovariectomized rats. Int J Heart. 2016;57:96–103.
18. Irgoyen PC, Paulini J, Flores LJ, Flues K, Bertagnolli M, Moreira ED, Consolim-Colombo F, Bello-Klein A, De Angelis K. Exercise training improves baroreflex sensitivity associated with oxidative stress reduction in ovariectomized rats. Hypertension. 2005;46:998–1003.
19. Hamilton KL, Lin L, Wang Y, Knolton AA. Effect of ovariectomy on cardiac gene expression: inflammation and changes in SOD gene expression. Physiol Genomics. 2008;32:254–63.
20. Zhu X, Tang Z, Cong B, Du J, Wang C, Wang L, Ni X, Lu J. Estrogens increase cystathionine-gamma-lyase expression and decrease inflammation and oxidative stress in the myocardium of ovariectomized rats. Menopause. 2013;20:1084–91.
21. Campos C, Casali KR, Baraldi D, Conzatti A, Araujo AS, Khaener N, Lleusy S, Rigatto K, Bello-Klein A. Efficacy of a low dose of estrogen on antioxidant defenses and heart rate variability. Oxidative Med Cell Longev. 2014;2014:218749.
22. Zheng LL, Teng Y, Tang GW, Zhang ZI, Choi WK, Cheng KL, Sze SC, Wai K, Liu Q, Yu BX. A randomized, double-blind, controlled trial of a Chinese herbal formula (Ex-Yian decoction) for menopausal symptoms in Hong Kong perimenopausal women. Menopause. 2013;20:767–76.
23. Wang SW, Cheung HP, Tong Y, Lu J, Ng TB, Zhang YB, Zhang ZJ, Lee KF, Lam JK, Sze SC. Stereodifferent effects of Exian decoction for relieving menopause via the p-Akt/PKB pathway in vitro and in vivo. J Ethnopharmacol. 2017;195:189–95.
24. Sze SC, Tong Y, Zhang YB, Zhang ZJ, Lau AS, Wong HK, Tsang KW, Ng TB. A novel mechanism: Exian decoction, a Chinese medicine formula, for relieving menopausal syndrome. J Ethnopharmacol. 2009;123:27–33.
25. Zhang ZG, Bai D, Liu MJ, Li Y, Pan JH, Liu H, Wang WL, Xiang LH, Xiao GG, Kong perimenopausal women. Menopause. 2013;20:767–76.
26. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanekusa M, KEGG, Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999;27:29–34.
27. Li A, Pickham D. Basic cardiac electrophysiology and common drug-induced arrhythmias. Crit Care Nurse Clin North Am. 2016;28:357–71.
28. Liu J, Laksman Z, Bocch Pitt. The electrophysiological development of cardiomyocytes. Adv Drug Deliv Rev. 2016;96:253–73.
29. El Gebeily G, El Khoury N, Mathieu S, Brouillette J, Fiset C. Estrogen metabolism of ovariectomized rats. Menopause. 2013;20:1084–91.
30.Turdi S, Huff AF, Pang J, He EY, Chen X, Wang S, Zhang Y, Ren J. Estrogen increases cardiomyocyte contractile function via activation of AMP-activated protein kinase. Toxicol Lett. 2015;232:253–62.
31. Wang KC, Lee KS, Luk HK, Wan HY, Ho CK, Zhang Y, Wong MS. Er-xian decoction exerts estrogen-like osteoprotective effects in vivo and in vitro. Am J Chin Med. 2014;42:409–26.
33. Huang CY, Lin YY, Hsu CC, Cheng SM, Shyu WC, Ting H, Yang AL, Ho TJ, Lee SD. Antiapoptotic effect of exercise training on ovariectomized rat hearts. J Appl Physiol. 2016;121:457–65.

34. Rattanasopa C, Phungphong S, Wattanapermpool J, Bupha-Intr T. Significant role of estrogen in maintaining cardiac mitochondrial functions. J Steroid Biochem Mol Biol. 2015;147:1–9.

35. Jessup JA, Wang H, MacNamara LM, Presley TD, Kim-Shapiro DB, Zhang L, Chen AF, Groban L. Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats. Menopause. 2013;20:860–8.

36. Ueyama T, Ishikura F, Matsuda A, Asanuma T, Ueda K, Ichinose M, Kasamatsu K, Hano T, Tsuruo Y, et al. Chronic estrogen supplementation following ovariectomy improves the emotional stress-induced cardiovascular responses by indirect action on the nervous system and by direct action on the heart. Circ J. 2007;71:565–73.

37. Raymont I, Holden HM, Whittaker M, Yohn CB, Lorenz M, Holmes KC, Milligan RA. Structure of the actin-myosin complex and its implications for muscle contraction. Science. 1993;261:58–65.

38. Yamauchi-Takihara K, Sole MJ, Liew CC. Characterization of human cardiac myosin heavy chain genes. Proc Natl Acad Sci U S A. 1989;86:3504–8.

39. Chang AN, Kamm KE, Stull JT. Role of myosin light chain phosphatase in cardiac physiology and pathophysiology. J Mol Cell Cardiol. 2016;101:35–43.

40. Kararigas G, Bitto V, Telin H, Becher E, Baczo I, Kossofa C, Albrecht-Kupper B, Sipido KR, Regitz-Zagrosek V. Transcriptome characterization of estrogen-treated human myocardium identifies myosin regulatory light chain interacting protein as a sex-specific element influencing contractile function. J Am Coll Cardiol. 2012;59:410–7.

41. Pandit S, Woranush W, Wattanapermpool J, Bupha-Intr T. Significant role of female sex hormones in cardiac myofilament activation in angiotensin II-mediated hypertensive rats. J Physiol Sci. 2014;64:269–77.

42. Thawornkaiwong A, Pantharanontaga J. Hypersensitivity of myofilament response to Ca2+ in association with maladaptation of estrogen-deficient heart under diabetes complication. Am J Physiol Regul Integr Comp Physiol. 2007;292:R844–51.

43. Schwab K, Stein R, Scheler C, Theuring F. Dietary genistein enhances phosphorylation of regulatory myosin light chain in the myocardium of ovariectomized mice. Electrophoresis. 2012;33:1795–803.

44. Duft K, Schanz M, Pham H, Abdelwahab A, Schriever C, Kararigas G, Dworatzek E, Davidson MM, Regitz-Zagrosek V, Morano I, et al. 17beta-estradiol-induced interaction of estrogen receptor alpha and human atrial essential myosin light chain modulates cardiac contractile function. Basic Res Cardiol. 2017;112:1.

45. Rehm N, Thawornkaiwong A, Pantharanontaga J, Wattanapermpool J. Cardioprotective effects of exercise training on myofilament calcium activation in ovariectomized rats. J Appl Physiol. 2004;96:1755–60.

46. Patten RD, Pourati I, Atronovitz MJ, Alsheikh-Ali A, Eder S, Force T, Mendelsohn ME, Karas RH. 17-Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail. 2008;14:245–53.

47. Iwamoto DV, Calderwood DA. Regulation of integrin-mediated adhesions. Curr Opin Cell Biol. 2015;36:41–7.

48. Israeli-Rosenberg S, Manso AM, Okada H, Ross RS. Integrins and integrin-associated proteins in the cardiac myocyte. Circ Res. 2014;114:572–86.

49. Hydes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–87.

50. Agarwal SK. Integrins and cadherins as therapeutic targets in fibrosis. Front Pharmacol. 2014;5:131.

51. Chen C, Li R, Ross RS, Manso AM. Integrins and integrin-related proteins in cardiac fibrosis. J Mol Cell Cardiol. 2016;93:162–74.